NASDAQ: CTCXCarmell Corp Stock
$0.45+0.01 (+2.27%)
Updated Jan 24, 2025
CTCX Price
$0.45
Fair Value Price
$0.07
Market Cap
$9.45M
52 Week Low
$0.20
52 Week High
$4.00
P/E
0.5x
P/B
-2.32x
P/S
-2.27x
PEG
N/A
Dividend Yield
N/A
Revenue
-$3.70M
Earnings
-$6.30M
Gross Margin
58.4%
Operating Margin
171.41%
Profit Margin
170.4%
Debt to Equity
-1.6
Operating Cash Flow
-$7M
Beta
0.17
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CTCX Overview
Alpha Healthcare Acquisition Corp. III is a "blank check" company formed to effect mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar combinations with one or more businesses. Ittargets the healthcare sector in the U.S. The company was incorporated in 2021 and is based in New York, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CTCX's potential to beat the market
- CTCX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CTCX
RankedUnranked of 555
RankedUnranked of 555
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $22.17 | A | |
| $122.04 | A | |
| $2.96 | A |
Be the first to know about important CTCX news, forecast changes, insider trades & much more!
CTCX News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CTCX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CTCX ($0.45) is overvalued by 541.94% relative to our estimate of its Fair Value price of $0.07 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CTCX ($0.45) is not significantly undervalued (541.94%) relative to our estimate of its Fair Value price of $0.07 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CTCX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
There are 30 more CTCX due diligence checks available for Premium users.
Valuation
CTCX fair value
Fair Value of CTCX stock based on Discounted Cash Flow (DCF)
Price
$0.45
Fair Value
$0.07
Overvalued by
539.10%
CTCX ($0.45) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CTCX ($0.45) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CTCX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.5x
Industry
-188.16x
Market
30.33x
CTCX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CTCX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
CTCX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-2.32x
Industry
5.04x
CTCX's financial health
Profit margin
Revenue
$20.5k
Net Income
-$2.9M
Profit Margin
-14,028.4%
CTCX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$2.4M
Liabilities
$6.5M
Debt to equity
-1.6
CTCX's short-term liabilities ($6.17M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CTCX's short-term assets ($1.88M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CTCX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CTCX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.4M
Investing
$0.0
Financing
$341.7k
CTCX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CTCX vs Biotech Stocks
Carmell Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.